AustralieFrV1, PascalFrancis, Corpus, bibRecord, 002E89

On a mouse monoclonal antibody that neutralizes all four dengue virus serotypes

Identifieur interne : 002E89 ( PascalFrancis/Corpus ); précédent : 002E88; suivant : 002E90

On a mouse monoclonal antibody that neutralizes all four dengue virus serotypes

Auteurs : Ravikumar Rajamanonmani ; Celine Nkenfou ; Paula Clancy ; YIN HOE YAU ; Susana Geifman Shochat ; Soila Sukupolvi-Petty ; Wouter Schul ; Michael S. Diamond ; Subhash G. Vasudevan ; Julien Lescar

Source :

Journal of general virology [ 0022-1317 ] ; 2009.

RBID : Pascal:09-0162365

Descripteurs français

Pascal (Inist)
- Souris, Virus dengue, Animal, Anticorps monoclonal, Sérotype, Microbiologie.

English descriptors

KwdEn :
- Animal, Dengue virus, Microbiology, Monoclonal antibody, Mouse, Serotype.

Abstract

The flavivirus envelope glycoprotein (E) is responsible for viral attachment and entry by membrane fusion. Its ectodomain is the primary target of the humoral immune response. In particular, the C-terminal Ig-like domain III of E, which is exposed at the surface of the viral particle, forms an attractive antigen for raising protective monoclonal antibodies (mAb). 9F12, a mouse mAb raised against a dengue virus (DENV) serotype 2 recombinant domain III, cross-reacts with corresponding domains from the other three DENV serotypes and also with West Nile virus. mAb 9F1 2 binds with nanomolar affinity to a conserved epitope that maps to the viral surface comprising residues 305, 307, 310 and 330 of the E protein. mAb 9F1 2 neutralizes all four DENV serotypes in plaque reduction assays. We expressed a single-chain Fv from 9F12 that retains the binding activity of the parent mAb. Adsorption and fusion inhibition assays indicate that mAb 9F1 2 prevents early steps of viral entry. Its virus inhibition activity and broad cross-reactivity makes mAb 9F12 a suitable candidate for optimization and humanization into a therapeutic antibody to treat severe infections by dengue.

Notice en format standard (ISO 2709)

Pour connaître la documentation sur le format Inist Standard.

A01	`01`	`1`		`@0 0022-1317`
A02	`01`			`@0 JGVIAY`
A03		`1`		`@0 J. gen. virol.`
A05				`@2 90`
A06				`@3 p. 4`
A08	`01`	`1`	`ENG`	`@1 On a mouse monoclonal antibody that neutralizes all four dengue virus serotypes`
A11	`01`	`1`		`@1 RAJAMANONMANI (Ravikumar)`
A11	`02`	`1`		`@1 NKENFOU (Celine)`
A11	`03`	`1`		`@1 CLANCY (Paula)`
A11	`04`	`1`		`@1 YIN HOE YAU`
A11	`05`	`1`		`@1 GEIFMAN SHOCHAT (Susana)`
A11	`06`	`1`		`@1 SUKUPOLVI-PETTY (Soila)`
A11	`07`	`1`		`@1 SCHUL (Wouter)`
A11	`08`	`1`		`@1 DIAMOND (Michael S.)`
A11	`09`	`1`		`@1 VASUDEVAN (Subhash G.)`
A11	`10`	`1`		`@1 LESCAR (Julien)`
A14	`01`			`@1 School of Biological Sciences, Nanyang Technological University @2 Biopolis @3 SGP @Z 1 aut. @Z 4 aut. @Z 5 aut. @Z 10 aut.`
A14	`02`			`@1 Program in Emerging Infectious Diseases, Duke-NUS, Graduate Medical School @3 SGP @Z 1 aut. @Z 9 aut.`
A14	`03`			`@1 Novartis Institute for Tropical Diseases @2 Biopolis @3 SGP @Z 2 aut. @Z 7 aut.`
A14	`04`			`@1 Department of Biochemistry and Molecular Biology, James Cook University @3 AUS @Z 3 aut. @Z 9 aut.`
A14	`05`			`@1 Departments of Medicine, Molecular Microbiology, Pathology and Immunology, Washington University School of Medicine @2 St Louis @3 USA @Z 6 aut. @Z 8 aut.`
A14	`06`			`@1 AFMB CNRS UMR6098 @2 Marseille @3 FRA @Z 10 aut.`
A20				`@1 799-809`
A21				`@1 2009`
A23	`01`			`@0 ENG`
A43	`01`			`@1 INIST @2 13533 @5 354000187410180030`
A44				`@0 0000 @1 © 2009 INIST-CNRS. All rights reserved.`
A45				`@0 1 p.3/4`
A47	`01`	`1`		`@0 09-0162365`
A60				`@1 P`
A61				`@0 A`
A64	`01`	`1`		`@0 Journal of general virology`
A66	`01`			`@0 GBR`
C01	`01`		`ENG`	@0 The flavivirus envelope glycoprotein (E) is responsible for viral attachment and entry by membrane fusion. Its ectodomain is the primary target of the humoral immune response. In particular, the C-terminal Ig-like domain III of E, which is exposed at the surface of the viral particle, forms an attractive antigen for raising protective monoclonal antibodies (mAb). 9F12, a mouse mAb raised against a dengue virus (DENV) serotype 2 recombinant domain III, cross-reacts with corresponding domains from the other three DENV serotypes and also with West Nile virus. mAb 9F1 2 binds with nanomolar affinity to a conserved epitope that maps to the viral surface comprising residues 305, 307, 310 and 330 of the E protein. mAb 9F1 2 neutralizes all four DENV serotypes in plaque reduction assays. We expressed a single-chain Fv from 9F12 that retains the binding activity of the parent mAb. Adsorption and fusion inhibition assays indicate that mAb 9F1 2 prevents early steps of viral entry. Its virus inhibition activity and broad cross-reactivity makes mAb 9F12 a suitable candidate for optimization and humanization into a therapeutic antibody to treat severe infections by dengue.
C02	`01`	`X`		`@0 002A05C10`
C02	`02`	`X`		`@0 002A05C07`
C03	`01`	`X`	`FRE`	`@0 Souris @5 01`
C03	`01`	`X`	`ENG`	`@0 Mouse @5 01`
C03	`01`	`X`	`SPA`	`@0 Ratón @5 01`
C03	`02`	`X`	`FRE`	`@0 Virus dengue @2 NW @5 02`
C03	`02`	`X`	`ENG`	`@0 Dengue virus @2 NW @5 02`
C03	`02`	`X`	`SPA`	`@0 Dengue virus @2 NW @5 02`
C03	`03`	`X`	`FRE`	`@0 Animal @5 05`
C03	`03`	`X`	`ENG`	`@0 Animal @5 05`
C03	`03`	`X`	`SPA`	`@0 Animal @5 05`
C03	`04`	`X`	`FRE`	`@0 Anticorps monoclonal @5 06`
C03	`04`	`X`	`ENG`	`@0 Monoclonal antibody @5 06`
C03	`04`	`X`	`SPA`	`@0 Anticuerpo monoclonal @5 06`
C03	`05`	`X`	`FRE`	`@0 Sérotype @5 07`
C03	`05`	`X`	`ENG`	`@0 Serotype @5 07`
C03	`05`	`X`	`SPA`	`@0 Serotipo @5 07`
C03	`06`	`X`	`FRE`	`@0 Microbiologie @5 08`
C03	`06`	`X`	`ENG`	`@0 Microbiology @5 08`
C03	`06`	`X`	`SPA`	`@0 Microbiología @5 08`
C07	`01`	`X`	`FRE`	`@0 Rodentia @2 NS`
C07	`01`	`X`	`ENG`	`@0 Rodentia @2 NS`
C07	`01`	`X`	`SPA`	`@0 Rodentia @2 NS`
C07	`02`	`X`	`FRE`	`@0 Mammalia @2 NS`
C07	`02`	`X`	`ENG`	`@0 Mammalia @2 NS`
C07	`02`	`X`	`SPA`	`@0 Mammalia @2 NS`
C07	`03`	`X`	`FRE`	`@0 Vertebrata @2 NS`
C07	`03`	`X`	`ENG`	`@0 Vertebrata @2 NS`
C07	`03`	`X`	`SPA`	`@0 Vertebrata @2 NS`
C07	`04`	`X`	`FRE`	`@0 Virus groupe dengue @2 NW`
C07	`04`	`X`	`ENG`	`@0 Dengue group virus @2 NW`
C07	`04`	`X`	`SPA`	`@0 Dengue group virus @2 NW`
C07	`05`	`X`	`FRE`	`@0 Flavivirus @2 NW`
C07	`05`	`X`	`ENG`	`@0 Flavivirus @2 NW`
C07	`05`	`X`	`SPA`	`@0 Flavivirus @2 NW`
C07	`06`	`X`	`FRE`	`@0 Flaviviridae @2 NW`
C07	`06`	`X`	`ENG`	`@0 Flaviviridae @2 NW`
C07	`06`	`X`	`SPA`	`@0 Flaviviridae @2 NW`
C07	`07`	`X`	`FRE`	`@0 Virus @2 NW`
C07	`07`	`X`	`ENG`	`@0 Virus @2 NW`
C07	`07`	`X`	`SPA`	`@0 Virus @2 NW`
N21				`@1 117`
N44	`01`			`@1 OTO`
N82				`@1 OTO`

Format Inist (serveur)

NO :	PASCAL 09-0162365 INIST
ET :	On a mouse monoclonal antibody that neutralizes all four dengue virus serotypes
AU :	RAJAMANONMANI (Ravikumar); NKENFOU (Celine); CLANCY (Paula); YIN HOE YAU; GEIFMAN SHOCHAT (Susana); SUKUPOLVI-PETTY (Soila); SCHUL (Wouter); DIAMOND (Michael S.); VASUDEVAN (Subhash G.); LESCAR (Julien)
AF :	School of Biological Sciences, Nanyang Technological University/Biopolis/Singapour (1 aut., 4 aut., 5 aut., 10 aut.); Program in Emerging Infectious Diseases, Duke-NUS, Graduate Medical School/Singapour (1 aut., 9 aut.); Novartis Institute for Tropical Diseases/Biopolis/Singapour (2 aut., 7 aut.); Department of Biochemistry and Molecular Biology, James Cook University/Australie (3 aut., 9 aut.); Departments of Medicine, Molecular Microbiology, Pathology and Immunology, Washington University School of Medicine/St Louis/Etats-Unis (6 aut., 8 aut.); AFMB CNRS UMR6098/Marseille/France (10 aut.)
DT :	Publication en série; Niveau analytique
SO :	Journal of general virology; ISSN 0022-1317; Coden JGVIAY; Royaume-Uni; Da. 2009; Vol. 90; No. p. 4; Pp. 799-809; Bibl. 1 p.3/4
LA :	Anglais
EA :	The flavivirus envelope glycoprotein (E) is responsible for viral attachment and entry by membrane fusion. Its ectodomain is the primary target of the humoral immune response. In particular, the C-terminal Ig-like domain III of E, which is exposed at the surface of the viral particle, forms an attractive antigen for raising protective monoclonal antibodies (mAb). 9F12, a mouse mAb raised against a dengue virus (DENV) serotype 2 recombinant domain III, cross-reacts with corresponding domains from the other three DENV serotypes and also with West Nile virus. mAb 9F1 2 binds with nanomolar affinity to a conserved epitope that maps to the viral surface comprising residues 305, 307, 310 and 330 of the E protein. mAb 9F1 2 neutralizes all four DENV serotypes in plaque reduction assays. We expressed a single-chain Fv from 9F12 that retains the binding activity of the parent mAb. Adsorption and fusion inhibition assays indicate that mAb 9F1 2 prevents early steps of viral entry. Its virus inhibition activity and broad cross-reactivity makes mAb 9F12 a suitable candidate for optimization and humanization into a therapeutic antibody to treat severe infections by dengue.
CC :	002A05C10; 002A05C07
FD :	Souris; Virus dengue; Animal; Anticorps monoclonal; Sérotype; Microbiologie
FG :	Rodentia; Mammalia; Vertebrata; Virus groupe dengue; Flavivirus; Flaviviridae; Virus
ED :	Mouse; Dengue virus; Animal; Monoclonal antibody; Serotype; Microbiology
EG :	Rodentia; Mammalia; Vertebrata; Dengue group virus; Flavivirus; Flaviviridae; Virus
SD :	Ratón; Dengue virus; Animal; Anticuerpo monoclonal; Serotipo; Microbiología
LO :	INIST-13533.354000187410180030
ID :	09-0162365

Links to Exploration step

Pascal:09-0162365

Le document en format XML

<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en" level="a">On a mouse monoclonal antibody that neutralizes all four dengue virus serotypes</title>
<author><name sortKey="Rajamanonmani, Ravikumar" sort="Rajamanonmani, Ravikumar" uniqKey="Rajamanonmani R" first="Ravikumar" last="Rajamanonmani">Ravikumar Rajamanonmani</name>
<affiliation><inist:fA14 i1="01"><s1>School of Biological Sciences, Nanyang Technological University</s1>
<s2>Biopolis</s2>
<s3>SGP</s3>
<sZ>1 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>10 aut.</sZ>
</inist:fA14>
</affiliation>
<affiliation><inist:fA14 i1="02"><s1>Program in Emerging Infectious Diseases, Duke-NUS, Graduate Medical School</s1>
<s3>SGP</s3>
<sZ>1 aut.</sZ>
<sZ>9 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Nkenfou, Celine" sort="Nkenfou, Celine" uniqKey="Nkenfou C" first="Celine" last="Nkenfou">Celine Nkenfou</name>
<affiliation><inist:fA14 i1="03"><s1>Novartis Institute for Tropical Diseases</s1>
<s2>Biopolis</s2>
<s3>SGP</s3>
<sZ>2 aut.</sZ>
<sZ>7 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Clancy, Paula" sort="Clancy, Paula" uniqKey="Clancy P" first="Paula" last="Clancy">Paula Clancy</name>
<affiliation><inist:fA14 i1="04"><s1>Department of Biochemistry and Molecular Biology, James Cook University</s1>
<s3>AUS</s3>
<sZ>3 aut.</sZ>
<sZ>9 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Yin Hoe Yau" sort="Yin Hoe Yau" uniqKey="Yin Hoe Yau" last="Yin Hoe Yau">YIN HOE YAU</name>
<affiliation><inist:fA14 i1="01"><s1>School of Biological Sciences, Nanyang Technological University</s1>
<s2>Biopolis</s2>
<s3>SGP</s3>
<sZ>1 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>10 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Geifman Shochat, Susana" sort="Geifman Shochat, Susana" uniqKey="Geifman Shochat S" first="Susana" last="Geifman Shochat">Susana Geifman Shochat</name>
<affiliation><inist:fA14 i1="01"><s1>School of Biological Sciences, Nanyang Technological University</s1>
<s2>Biopolis</s2>
<s3>SGP</s3>
<sZ>1 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>10 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Sukupolvi Petty, Soila" sort="Sukupolvi Petty, Soila" uniqKey="Sukupolvi Petty S" first="Soila" last="Sukupolvi-Petty">Soila Sukupolvi-Petty</name>
<affiliation><inist:fA14 i1="05"><s1>Departments of Medicine, Molecular Microbiology, Pathology and Immunology, Washington University School of Medicine</s1>
<s2>St Louis</s2>
<s3>USA</s3>
<sZ>6 aut.</sZ>
<sZ>8 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Schul, Wouter" sort="Schul, Wouter" uniqKey="Schul W" first="Wouter" last="Schul">Wouter Schul</name>
<affiliation><inist:fA14 i1="03"><s1>Novartis Institute for Tropical Diseases</s1>
<s2>Biopolis</s2>
<s3>SGP</s3>
<sZ>2 aut.</sZ>
<sZ>7 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Diamond, Michael S" sort="Diamond, Michael S" uniqKey="Diamond M" first="Michael S." last="Diamond">Michael S. Diamond</name>
<affiliation><inist:fA14 i1="05"><s1>Departments of Medicine, Molecular Microbiology, Pathology and Immunology, Washington University School of Medicine</s1>
<s2>St Louis</s2>
<s3>USA</s3>
<sZ>6 aut.</sZ>
<sZ>8 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Vasudevan, Subhash G" sort="Vasudevan, Subhash G" uniqKey="Vasudevan S" first="Subhash G." last="Vasudevan">Subhash G. Vasudevan</name>
<affiliation><inist:fA14 i1="02"><s1>Program in Emerging Infectious Diseases, Duke-NUS, Graduate Medical School</s1>
<s3>SGP</s3>
<sZ>1 aut.</sZ>
<sZ>9 aut.</sZ>
</inist:fA14>
</affiliation>
<affiliation><inist:fA14 i1="04"><s1>Department of Biochemistry and Molecular Biology, James Cook University</s1>
<s3>AUS</s3>
<sZ>3 aut.</sZ>
<sZ>9 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Lescar, Julien" sort="Lescar, Julien" uniqKey="Lescar J" first="Julien" last="Lescar">Julien Lescar</name>
<affiliation><inist:fA14 i1="01"><s1>School of Biological Sciences, Nanyang Technological University</s1>
<s2>Biopolis</s2>
<s3>SGP</s3>
<sZ>1 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>10 aut.</sZ>
</inist:fA14>
</affiliation>
<affiliation><inist:fA14 i1="06"><s1>AFMB CNRS UMR6098</s1>
<s2>Marseille</s2>
<s3>FRA</s3>
<sZ>10 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">INIST</idno>
<idno type="inist">09-0162365</idno>
<date when="2009">2009</date>
<idno type="stanalyst">PASCAL 09-0162365 INIST</idno>
<idno type="RBID">Pascal:09-0162365</idno>
<idno type="wicri:Area/PascalFrancis/Corpus">002E89</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en" level="a">On a mouse monoclonal antibody that neutralizes all four dengue virus serotypes</title>
<author><name sortKey="Rajamanonmani, Ravikumar" sort="Rajamanonmani, Ravikumar" uniqKey="Rajamanonmani R" first="Ravikumar" last="Rajamanonmani">Ravikumar Rajamanonmani</name>
<affiliation><inist:fA14 i1="01"><s1>School of Biological Sciences, Nanyang Technological University</s1>
<s2>Biopolis</s2>
<s3>SGP</s3>
<sZ>1 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>10 aut.</sZ>
</inist:fA14>
</affiliation>
<affiliation><inist:fA14 i1="02"><s1>Program in Emerging Infectious Diseases, Duke-NUS, Graduate Medical School</s1>
<s3>SGP</s3>
<sZ>1 aut.</sZ>
<sZ>9 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Nkenfou, Celine" sort="Nkenfou, Celine" uniqKey="Nkenfou C" first="Celine" last="Nkenfou">Celine Nkenfou</name>
<affiliation><inist:fA14 i1="03"><s1>Novartis Institute for Tropical Diseases</s1>
<s2>Biopolis</s2>
<s3>SGP</s3>
<sZ>2 aut.</sZ>
<sZ>7 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Clancy, Paula" sort="Clancy, Paula" uniqKey="Clancy P" first="Paula" last="Clancy">Paula Clancy</name>
<affiliation><inist:fA14 i1="04"><s1>Department of Biochemistry and Molecular Biology, James Cook University</s1>
<s3>AUS</s3>
<sZ>3 aut.</sZ>
<sZ>9 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Yin Hoe Yau" sort="Yin Hoe Yau" uniqKey="Yin Hoe Yau" last="Yin Hoe Yau">YIN HOE YAU</name>
<affiliation><inist:fA14 i1="01"><s1>School of Biological Sciences, Nanyang Technological University</s1>
<s2>Biopolis</s2>
<s3>SGP</s3>
<sZ>1 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>10 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Geifman Shochat, Susana" sort="Geifman Shochat, Susana" uniqKey="Geifman Shochat S" first="Susana" last="Geifman Shochat">Susana Geifman Shochat</name>
<affiliation><inist:fA14 i1="01"><s1>School of Biological Sciences, Nanyang Technological University</s1>
<s2>Biopolis</s2>
<s3>SGP</s3>
<sZ>1 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>10 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Sukupolvi Petty, Soila" sort="Sukupolvi Petty, Soila" uniqKey="Sukupolvi Petty S" first="Soila" last="Sukupolvi-Petty">Soila Sukupolvi-Petty</name>
<affiliation><inist:fA14 i1="05"><s1>Departments of Medicine, Molecular Microbiology, Pathology and Immunology, Washington University School of Medicine</s1>
<s2>St Louis</s2>
<s3>USA</s3>
<sZ>6 aut.</sZ>
<sZ>8 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Schul, Wouter" sort="Schul, Wouter" uniqKey="Schul W" first="Wouter" last="Schul">Wouter Schul</name>
<affiliation><inist:fA14 i1="03"><s1>Novartis Institute for Tropical Diseases</s1>
<s2>Biopolis</s2>
<s3>SGP</s3>
<sZ>2 aut.</sZ>
<sZ>7 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Diamond, Michael S" sort="Diamond, Michael S" uniqKey="Diamond M" first="Michael S." last="Diamond">Michael S. Diamond</name>
<affiliation><inist:fA14 i1="05"><s1>Departments of Medicine, Molecular Microbiology, Pathology and Immunology, Washington University School of Medicine</s1>
<s2>St Louis</s2>
<s3>USA</s3>
<sZ>6 aut.</sZ>
<sZ>8 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Vasudevan, Subhash G" sort="Vasudevan, Subhash G" uniqKey="Vasudevan S" first="Subhash G." last="Vasudevan">Subhash G. Vasudevan</name>
<affiliation><inist:fA14 i1="02"><s1>Program in Emerging Infectious Diseases, Duke-NUS, Graduate Medical School</s1>
<s3>SGP</s3>
<sZ>1 aut.</sZ>
<sZ>9 aut.</sZ>
</inist:fA14>
</affiliation>
<affiliation><inist:fA14 i1="04"><s1>Department of Biochemistry and Molecular Biology, James Cook University</s1>
<s3>AUS</s3>
<sZ>3 aut.</sZ>
<sZ>9 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Lescar, Julien" sort="Lescar, Julien" uniqKey="Lescar J" first="Julien" last="Lescar">Julien Lescar</name>
<affiliation><inist:fA14 i1="01"><s1>School of Biological Sciences, Nanyang Technological University</s1>
<s2>Biopolis</s2>
<s3>SGP</s3>
<sZ>1 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>10 aut.</sZ>
</inist:fA14>
</affiliation>
<affiliation><inist:fA14 i1="06"><s1>AFMB CNRS UMR6098</s1>
<s2>Marseille</s2>
<s3>FRA</s3>
<sZ>10 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
</analytic>
<series><title level="j" type="main">Journal of general virology</title>
<title level="j" type="abbreviated">J. gen. virol.</title>
<idno type="ISSN">0022-1317</idno>
<imprint><date when="2009">2009</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
<seriesStmt><title level="j" type="main">Journal of general virology</title>
<title level="j" type="abbreviated">J. gen. virol.</title>
<idno type="ISSN">0022-1317</idno>
</seriesStmt>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Animal</term>
<term>Dengue virus</term>
<term>Microbiology</term>
<term>Monoclonal antibody</term>
<term>Mouse</term>
<term>Serotype</term>
</keywords>
<keywords scheme="Pascal" xml:lang="fr"><term>Souris</term>
<term>Virus dengue</term>
<term>Animal</term>
<term>Anticorps monoclonal</term>
<term>Sérotype</term>
<term>Microbiologie</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">The flavivirus envelope glycoprotein (E) is responsible for viral attachment and entry by membrane fusion. Its ectodomain is the primary target of the humoral immune response. In particular, the C-terminal Ig-like domain III of E, which is exposed at the surface of the viral particle, forms an attractive antigen for raising protective monoclonal antibodies (mAb). 9F12, a mouse mAb raised against a dengue virus (DENV) serotype 2 recombinant domain III, cross-reacts with corresponding domains from the other three DENV serotypes and also with West Nile virus. mAb 9F1 2 binds with nanomolar affinity to a conserved epitope that maps to the viral surface comprising residues 305, 307, 310 and 330 of the E protein. mAb 9F1 2 neutralizes all four DENV serotypes in plaque reduction assays. We expressed a single-chain Fv from 9F12 that retains the binding activity of the parent mAb. Adsorption and fusion inhibition assays indicate that mAb 9F1 2 prevents early steps of viral entry. Its virus inhibition activity and broad cross-reactivity makes mAb 9F12 a suitable candidate for optimization and humanization into a therapeutic antibody to treat severe infections by dengue.</div>
</front>
</TEI>
<inist><standard h6="B"><pA><fA01 i1="01" i2="1"><s0>0022-1317</s0>
</fA01>
<fA02 i1="01"><s0>JGVIAY</s0>
</fA02>
<fA03 i2="1"><s0>J. gen. virol.</s0>
</fA03>
<fA05><s2>90</s2>
</fA05>
<fA06><s3>p. 4</s3>
</fA06>
<fA08 i1="01" i2="1" l="ENG"><s1>On a mouse monoclonal antibody that neutralizes all four dengue virus serotypes</s1>
</fA08>
<fA11 i1="01" i2="1"><s1>RAJAMANONMANI (Ravikumar)</s1>
</fA11>
<fA11 i1="02" i2="1"><s1>NKENFOU (Celine)</s1>
</fA11>
<fA11 i1="03" i2="1"><s1>CLANCY (Paula)</s1>
</fA11>
<fA11 i1="04" i2="1"><s1>YIN HOE YAU</s1>
</fA11>
<fA11 i1="05" i2="1"><s1>GEIFMAN SHOCHAT (Susana)</s1>
</fA11>
<fA11 i1="06" i2="1"><s1>SUKUPOLVI-PETTY (Soila)</s1>
</fA11>
<fA11 i1="07" i2="1"><s1>SCHUL (Wouter)</s1>
</fA11>
<fA11 i1="08" i2="1"><s1>DIAMOND (Michael S.)</s1>
</fA11>
<fA11 i1="09" i2="1"><s1>VASUDEVAN (Subhash G.)</s1>
</fA11>
<fA11 i1="10" i2="1"><s1>LESCAR (Julien)</s1>
</fA11>
<fA14 i1="01"><s1>School of Biological Sciences, Nanyang Technological University</s1>
<s2>Biopolis</s2>
<s3>SGP</s3>
<sZ>1 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>10 aut.</sZ>
</fA14>
<fA14 i1="02"><s1>Program in Emerging Infectious Diseases, Duke-NUS, Graduate Medical School</s1>
<s3>SGP</s3>
<sZ>1 aut.</sZ>
<sZ>9 aut.</sZ>
</fA14>
<fA14 i1="03"><s1>Novartis Institute for Tropical Diseases</s1>
<s2>Biopolis</s2>
<s3>SGP</s3>
<sZ>2 aut.</sZ>
<sZ>7 aut.</sZ>
</fA14>
<fA14 i1="04"><s1>Department of Biochemistry and Molecular Biology, James Cook University</s1>
<s3>AUS</s3>
<sZ>3 aut.</sZ>
<sZ>9 aut.</sZ>
</fA14>
<fA14 i1="05"><s1>Departments of Medicine, Molecular Microbiology, Pathology and Immunology, Washington University School of Medicine</s1>
<s2>St Louis</s2>
<s3>USA</s3>
<sZ>6 aut.</sZ>
<sZ>8 aut.</sZ>
</fA14>
<fA14 i1="06"><s1>AFMB CNRS UMR6098</s1>
<s2>Marseille</s2>
<s3>FRA</s3>
<sZ>10 aut.</sZ>
</fA14>
<fA20><s1>799-809</s1>
</fA20>
<fA21><s1>2009</s1>
</fA21>
<fA23 i1="01"><s0>ENG</s0>
</fA23>
<fA43 i1="01"><s1>INIST</s1>
<s2>13533</s2>
<s5>354000187410180030</s5>
</fA43>
<fA44><s0>0000</s0>
<s1>© 2009 INIST-CNRS. All rights reserved.</s1>
</fA44>
<fA45><s0>1 p.3/4</s0>
</fA45>
<fA47 i1="01" i2="1"><s0>09-0162365</s0>
</fA47>
<fA60><s1>P</s1>
</fA60>
<fA61><s0>A</s0>
</fA61>
<fA64 i1="01" i2="1"><s0>Journal of general virology</s0>
</fA64>
<fA66 i1="01"><s0>GBR</s0>
</fA66>
<fC01 i1="01" l="ENG"><s0>The flavivirus envelope glycoprotein (E) is responsible for viral attachment and entry by membrane fusion. Its ectodomain is the primary target of the humoral immune response. In particular, the C-terminal Ig-like domain III of E, which is exposed at the surface of the viral particle, forms an attractive antigen for raising protective monoclonal antibodies (mAb). 9F12, a mouse mAb raised against a dengue virus (DENV) serotype 2 recombinant domain III, cross-reacts with corresponding domains from the other three DENV serotypes and also with West Nile virus. mAb 9F1 2 binds with nanomolar affinity to a conserved epitope that maps to the viral surface comprising residues 305, 307, 310 and 330 of the E protein. mAb 9F1 2 neutralizes all four DENV serotypes in plaque reduction assays. We expressed a single-chain Fv from 9F12 that retains the binding activity of the parent mAb. Adsorption and fusion inhibition assays indicate that mAb 9F1 2 prevents early steps of viral entry. Its virus inhibition activity and broad cross-reactivity makes mAb 9F12 a suitable candidate for optimization and humanization into a therapeutic antibody to treat severe infections by dengue.</s0>
</fC01>
<fC02 i1="01" i2="X"><s0>002A05C10</s0>
</fC02>
<fC02 i1="02" i2="X"><s0>002A05C07</s0>
</fC02>
<fC03 i1="01" i2="X" l="FRE"><s0>Souris</s0>
<s5>01</s5>
</fC03>
<fC03 i1="01" i2="X" l="ENG"><s0>Mouse</s0>
<s5>01</s5>
</fC03>
<fC03 i1="01" i2="X" l="SPA"><s0>Ratón</s0>
<s5>01</s5>
</fC03>
<fC03 i1="02" i2="X" l="FRE"><s0>Virus dengue</s0>
<s2>NW</s2>
<s5>02</s5>
</fC03>
<fC03 i1="02" i2="X" l="ENG"><s0>Dengue virus</s0>
<s2>NW</s2>
<s5>02</s5>
</fC03>
<fC03 i1="02" i2="X" l="SPA"><s0>Dengue virus</s0>
<s2>NW</s2>
<s5>02</s5>
</fC03>
<fC03 i1="03" i2="X" l="FRE"><s0>Animal</s0>
<s5>05</s5>
</fC03>
<fC03 i1="03" i2="X" l="ENG"><s0>Animal</s0>
<s5>05</s5>
</fC03>
<fC03 i1="03" i2="X" l="SPA"><s0>Animal</s0>
<s5>05</s5>
</fC03>
<fC03 i1="04" i2="X" l="FRE"><s0>Anticorps monoclonal</s0>
<s5>06</s5>
</fC03>
<fC03 i1="04" i2="X" l="ENG"><s0>Monoclonal antibody</s0>
<s5>06</s5>
</fC03>
<fC03 i1="04" i2="X" l="SPA"><s0>Anticuerpo monoclonal</s0>
<s5>06</s5>
</fC03>
<fC03 i1="05" i2="X" l="FRE"><s0>Sérotype</s0>
<s5>07</s5>
</fC03>
<fC03 i1="05" i2="X" l="ENG"><s0>Serotype</s0>
<s5>07</s5>
</fC03>
<fC03 i1="05" i2="X" l="SPA"><s0>Serotipo</s0>
<s5>07</s5>
</fC03>
<fC03 i1="06" i2="X" l="FRE"><s0>Microbiologie</s0>
<s5>08</s5>
</fC03>
<fC03 i1="06" i2="X" l="ENG"><s0>Microbiology</s0>
<s5>08</s5>
</fC03>
<fC03 i1="06" i2="X" l="SPA"><s0>Microbiología</s0>
<s5>08</s5>
</fC03>
<fC07 i1="01" i2="X" l="FRE"><s0>Rodentia</s0>
<s2>NS</s2>
</fC07>
<fC07 i1="01" i2="X" l="ENG"><s0>Rodentia</s0>
<s2>NS</s2>
</fC07>
<fC07 i1="01" i2="X" l="SPA"><s0>Rodentia</s0>
<s2>NS</s2>
</fC07>
<fC07 i1="02" i2="X" l="FRE"><s0>Mammalia</s0>
<s2>NS</s2>
</fC07>
<fC07 i1="02" i2="X" l="ENG"><s0>Mammalia</s0>
<s2>NS</s2>
</fC07>
<fC07 i1="02" i2="X" l="SPA"><s0>Mammalia</s0>
<s2>NS</s2>
</fC07>
<fC07 i1="03" i2="X" l="FRE"><s0>Vertebrata</s0>
<s2>NS</s2>
</fC07>
<fC07 i1="03" i2="X" l="ENG"><s0>Vertebrata</s0>
<s2>NS</s2>
</fC07>
<fC07 i1="03" i2="X" l="SPA"><s0>Vertebrata</s0>
<s2>NS</s2>
</fC07>
<fC07 i1="04" i2="X" l="FRE"><s0>Virus groupe dengue</s0>
<s2>NW</s2>
</fC07>
<fC07 i1="04" i2="X" l="ENG"><s0>Dengue group virus</s0>
<s2>NW</s2>
</fC07>
<fC07 i1="04" i2="X" l="SPA"><s0>Dengue group virus</s0>
<s2>NW</s2>
</fC07>
<fC07 i1="05" i2="X" l="FRE"><s0>Flavivirus</s0>
<s2>NW</s2>
</fC07>
<fC07 i1="05" i2="X" l="ENG"><s0>Flavivirus</s0>
<s2>NW</s2>
</fC07>
<fC07 i1="05" i2="X" l="SPA"><s0>Flavivirus</s0>
<s2>NW</s2>
</fC07>
<fC07 i1="06" i2="X" l="FRE"><s0>Flaviviridae</s0>
<s2>NW</s2>
</fC07>
<fC07 i1="06" i2="X" l="ENG"><s0>Flaviviridae</s0>
<s2>NW</s2>
</fC07>
<fC07 i1="06" i2="X" l="SPA"><s0>Flaviviridae</s0>
<s2>NW</s2>
</fC07>
<fC07 i1="07" i2="X" l="FRE"><s0>Virus</s0>
<s2>NW</s2>
</fC07>
<fC07 i1="07" i2="X" l="ENG"><s0>Virus</s0>
<s2>NW</s2>
</fC07>
<fC07 i1="07" i2="X" l="SPA"><s0>Virus</s0>
<s2>NW</s2>
</fC07>
<fN21><s1>117</s1>
</fN21>
<fN44 i1="01"><s1>OTO</s1>
</fN44>
<fN82><s1>OTO</s1>
</fN82>
</pA>
</standard>
<server><NO>PASCAL 09-0162365 INIST</NO>
<ET>On a mouse monoclonal antibody that neutralizes all four dengue virus serotypes</ET>
<AU>RAJAMANONMANI (Ravikumar); NKENFOU (Celine); CLANCY (Paula); YIN HOE YAU; GEIFMAN SHOCHAT (Susana); SUKUPOLVI-PETTY (Soila); SCHUL (Wouter); DIAMOND (Michael S.); VASUDEVAN (Subhash G.); LESCAR (Julien)</AU>
<AF>School of Biological Sciences, Nanyang Technological University/Biopolis/Singapour (1 aut., 4 aut., 5 aut., 10 aut.); Program in Emerging Infectious Diseases, Duke-NUS, Graduate Medical School/Singapour (1 aut., 9 aut.); Novartis Institute for Tropical Diseases/Biopolis/Singapour (2 aut., 7 aut.); Department of Biochemistry and Molecular Biology, James Cook University/Australie (3 aut., 9 aut.); Departments of Medicine, Molecular Microbiology, Pathology and Immunology, Washington University School of Medicine/St Louis/Etats-Unis (6 aut., 8 aut.); AFMB CNRS UMR6098/Marseille/France (10 aut.)</AF>
<DT>Publication en série; Niveau analytique</DT>
<SO>Journal of general virology; ISSN 0022-1317; Coden JGVIAY; Royaume-Uni; Da. 2009; Vol. 90; No. p. 4; Pp. 799-809; Bibl. 1 p.3/4</SO>
<LA>Anglais</LA>
<EA>The flavivirus envelope glycoprotein (E) is responsible for viral attachment and entry by membrane fusion. Its ectodomain is the primary target of the humoral immune response. In particular, the C-terminal Ig-like domain III of E, which is exposed at the surface of the viral particle, forms an attractive antigen for raising protective monoclonal antibodies (mAb). 9F12, a mouse mAb raised against a dengue virus (DENV) serotype 2 recombinant domain III, cross-reacts with corresponding domains from the other three DENV serotypes and also with West Nile virus. mAb 9F1 2 binds with nanomolar affinity to a conserved epitope that maps to the viral surface comprising residues 305, 307, 310 and 330 of the E protein. mAb 9F1 2 neutralizes all four DENV serotypes in plaque reduction assays. We expressed a single-chain Fv from 9F12 that retains the binding activity of the parent mAb. Adsorption and fusion inhibition assays indicate that mAb 9F1 2 prevents early steps of viral entry. Its virus inhibition activity and broad cross-reactivity makes mAb 9F12 a suitable candidate for optimization and humanization into a therapeutic antibody to treat severe infections by dengue.</EA>
<CC>002A05C10; 002A05C07</CC>
<FD>Souris; Virus dengue; Animal; Anticorps monoclonal; Sérotype; Microbiologie</FD>
<FG>Rodentia; Mammalia; Vertebrata; Virus groupe dengue; Flavivirus; Flaviviridae; Virus</FG>
<ED>Mouse; Dengue virus; Animal; Monoclonal antibody; Serotype; Microbiology</ED>
<EG>Rodentia; Mammalia; Vertebrata; Dengue group virus; Flavivirus; Flaviviridae; Virus</EG>
<SD>Ratón; Dengue virus; Animal; Anticuerpo monoclonal; Serotipo; Microbiología</SD>
<LO>INIST-13533.354000187410180030</LO>
<ID>09-0162365</ID>
</server>
</inist>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Wicri/Asie/explor/AustralieFrV1/Data/PascalFrancis/Corpus

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 002E89 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/PascalFrancis/Corpus/biblio.hfd -nk 002E89 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Wicri/Asie
   |area=    AustralieFrV1
   |flux=    PascalFrancis
   |étape=   Corpus
   |type=    RBID
   |clé=     Pascal:09-0162365
   |texte=   On a mouse monoclonal antibody that neutralizes all four dengue virus serotypes
}}

This area was generated with Dilib version V0.6.33.
Data generation: Tue Dec 5 10:43:12 2017. Site generation: Tue Mar 5 14:07:20 2024

	Serveur d'exploration sur les relations entre la France et l'Australie
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.

Serveur d'exploration sur les relations entre la France et l'Australie

On a mouse monoclonal antibody that neutralizes all four dengue virus serotypes

On a mouse monoclonal antibody that neutralizes all four dengue virus serotypes

Source :

Descripteurs français

English descriptors

Abstract

Notice en format standard (ISO 2709)

Format Inist (serveur)

Links to Exploration step

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri